PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research

Illumina to Gain Exclusive, Licensed Access to Biomarkers Discovered Through Disease Studies

27-Oct-2005

Illumina, Inc. announced an agreement of sale with PharmacoDesign (PD) for a BeadStation system and whole-genome genotyping arrays and reagents for ongoing pharmacogenomics studies. PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation and personalizing treatment for optimal clinical outcomes.

Under the agreement, Illumina will gain access to biomarkers discovered by PD and will be able to incorporate such markers into proprietary SNP panels under a worldwide, royalty-bearing exclusive license.

PD will study diseases that include obesity, cancer and allergy-induced reactions such as atopy. The company works in partnership with large Korean hospitals to prescribe individualized treatments that utilize diet and "functional foods" in addition to traditional pharmacological approaches.

Other news from the department business & finance

These products might interest you

Blotting standards and reagents

Blotting standards and reagents by Cytiva

Western blotting standards and reagents

Blotting the course to effective detection of proteins from sample preparation to analysis

reagents
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
Greener Alternative Products

Greener Alternative Products by Merck

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
Loading...

Most read news

More news from our other portals